MIT researchers have developed a method to measure blood glucose noninvasively — without a needle — that could significantly reduce the daily burden of finger-prick testing for people with diabetes. The key innovation is using Raman spectroscopy to selectively read glucose-related signals from the skin, and achieving accuracy comparable to commercial invasive sensors with a device no larger than a shoebox — far smaller than previous setups. The team has already developed a phone-sized wearable prototype and is conducting additional clinical trials, with the long-term goal of shrinking the device to watch size.

1. "Sticking a Needle Every Day — Who Would Want That?" — Where the Problem Begins 🩸

The article opens with a painfully relatable frustration. For people with diabetes, blood glucose monitoring is a matter of survival — yet the reality of having to lance a finger and draw blood creates a major barrier. As a result, many patients don't test frequently enough, which can lead to serious complications.

MIT researcher Jeon Woong Kang puts it directly:

"Finger-pricking has long been the standard for glucose monitoring, but nobody wants to prick their finger every day, multiple times a day. Naturally, many diabetic patients end up not testing enough, and that can lead to serious complications."

The goal is equally clear: if a highly accurate noninvasive glucose monitor becomes possible, nearly every person with diabetes could benefit.

"If we can build a noninvasive glucose monitor with high accuracy, almost everyone living with diabetes will benefit from this new technology."

The study's first author is MIT postdoc Arianna Bresci, and the results were published in the journal Analytical Chemistry. Co-authors and institutional collaborators include MIT's Laser Biomedical Research Center (LBRC) and Korean biotech company Apollon Inc., among others.

2. The Core Technology: Reading Tissue Chemistry "Without Drawing Blood" via Raman Spectroscopy 🔦

The central tool the team uses is Raman spectroscopy. In simple terms, near-infrared (or visible) light is shone onto the skin, and the way that light scatters as it interacts with molecules in the tissue is analyzed to infer the chemical composition — including glucose levels.

The article describes it as follows:

• Raman spectroscopy reveals the chemical composition of tissue
• Light directed at the skin is analyzed as it bounces back, altered by interactions with molecules
• From this, glucose-related signals can be extracted

The critical promise: if this works reliably, blood glucose could be measured without any needle at all.

3. From Prior Work to Now: A Path from "Indirect Calculation → Direct Signal Detection → Miniaturization"

MIT's Laser Biomedical Research Center (LBRC) has been working in this space for years. The progression looks like this:

3-1. 2010: Blood Glucose "Indirectly Calculated" from Raman Signals — Reliable but Not Practical

In 2010, LBRC researchers showed that Raman signals from the interstitial fluid surrounding skin cells, compared against reference blood glucose readings, could be used to indirectly calculate glucose levels. However, the article notes that while this approach was "reliable," it was not practical enough to build into a real glucose monitor.

3-2. More Recently: A Breakthrough for "Directly" Measuring Glucose Raman Signals from Skin

The bigger advance came later. Glucose signals are inherently very weak compared to signals from other tissue molecules, making them easy to drown out. MIT's team found a way to filter out much of the unwanted signal by using different angles for delivering light versus collecting the scattered return signal.

In other words, they found a way to reduce "skin noise" and read the glucose signal directly.

3-3. But the Equipment Was Too Large → This Study Aims for "Smaller and Cheaper"

That direct detection was a success — but the equipment at the time was roughly the size of a desktop printer. The team has continued working to shrink the device, and this latest paper represents a significant step forward.

4. The Key Advance in This Paper: Instead of 1,000 Bands, Look at Just "3 Bands" 📉

A Raman spectrum can contain roughly 1,000 bands (spectral intervals), but the team concluded that most of those contain redundant information and boldly cut them down.

In this study, they reduced the spectral bands needed for glucose estimation to just three:

• 1 band: glucose signal
• 2 bands: background measurement signals

This simplification allows the hardware to be far less complex, reduces the number of required components and cost, and ultimately makes a shoebox-sized, cost-effective device feasible.

Researcher Bresci summarizes the key insight:

"Instead of capturing the full spectrum with all its redundant information, we narrowed it down to three selected bands out of roughly 1,000. This new approach lets us replace common components used in Raman-based devices and saves space, time, and cost."

The core strategy: don't look at everything — look only at what matters. It's a design philosophy that pursues miniaturization and lower cost without sacrificing performance.

5. Human Testing: Measurements Every 5 Minutes for 4 Hours, With Accuracy "Comparable to Commercial Invasive Sensors" 🧪

The next question is how well the device actually works on real people.

In a clinical study at MIT's Clinical and Translational Research Center (CCTR), the team ran a measurement experiment on one healthy volunteer over four hours.

The procedure worked as follows:

• The subject rested their arm on top of the device
• A near-infrared beam was delivered into the skin through a small glass window
• Each measurement took just over 30 seconds
• A new measurement was taken every 5 minutes

To produce meaningful swings in glucose levels, the subject drank a 75g glucose beverage twice during the session — creating clear rises and falls in blood glucose that the device needed to track.

The results were promising. The noninvasive Raman-based device achieved accuracy comparable to two commercial invasive continuous glucose monitors (CGMs) — which require insertion of a wire or sensor under the skin — worn simultaneously by the subject.

6. What's Next: Phone-Sized Wearable → Larger Clinical Trial in 2027 → Watch-Size Goal ⌚

The article's second half outlines the roadmap toward a real product.

• The device described in this paper is still too large for wearable use (shoebox-sized)
• But the team has already built a phone-sized smaller prototype and is currently running wearable-form trials at CCTR with healthy volunteers and prediabetic participants
• Next year (2027), a larger study involving patients with diabetes is planned in collaboration with a local hospital

The paper also clearly identifies the challenges ahead:

• Shrinking the device to watch size
• Ensuring accurate readings across people with different skin tones

The article closes by noting that the research received funding from the NIH (National Institutes of Health), Korea's Small and Medium Business Technology Information Promotion Agency, Apollon Inc., and others.

7. (Background Context) The Limits of Current Glucose Monitoring: Convenient but Either "Invasive" or "Inconvenient"

The article also provides context on the methods in widespread use today:

• Most common method: Draw blood and read it with a glucometer — accurate, but requires repeated finger pricks
• Used by some: Wearable continuous glucose monitors (CGMs) with a sensor inserted just under the skin
  • Measures interstitial fluid and provides continuous data
  • But can cause skin irritation or inflammation
  • Requires replacement every 10–15 days

Against this backdrop, MIT's goal is to offer an alternative that delivers both convenience (noninvasive) and accuracy at the same time.

8. Conclusion: The "3-Band" Strategy Brings Noninvasive Glucose Monitoring Closer to Reality

This MIT study demonstrates that Raman spectroscopy-based glucose monitoring can work with a device that is small (shoebox-sized) and lower-cost, by measuring just three key spectral bands instead of the full spectrum. In tests on a healthy volunteer, it matched the accuracy of commercial invasive continuous glucose monitors. The team is already testing a phone-sized wearable and plans a larger clinical trial including diabetic patients in 2027. The remaining milestones — shrinking to watch size and ensuring reliable accuracy across diverse skin tones — will be the critical gates ahead.